Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Paul R. Hutson"'
Autor:
Alyssa E. Jenkins, Cameron O. Scarlett, Tyler G. Beames, Kenneth S. Rivera-González, Alexander A. Martin, Miranda R. Sun, Paul R. Hutson, Robert J. Lipinski
Publikováno v:
Toxicology Reports, Vol 11, Iss , Pp 310-317 (2023)
Piperonyl butoxide (PBO) is a popular insecticide synergist present in thousands of commercial, agricultural, and household products. PBO inhibits cytochrome P450 activity, impairing the ability of insects to detoxify insecticides. PBO was recently d
Externí odkaz:
https://doaj.org/article/d969be1796154876ab493f0125a82c11
Autor:
Warren E. Rose, Paul R. Hutson
Publikováno v:
Drugs - Real World Outcomes, Vol 7, Iss S1, Pp 36-40 (2020)
Abstract Background Antibiotics for the treatment of complicated, multidrug-resistant Gram-positive infections are limited, especially when prolonged treatment is necessary. Oritavancin is approved for the treatment of serious skin infections as a 12
Externí odkaz:
https://doaj.org/article/3c92815a67d84f3c857553ad9bb666a4
Autor:
Michael W. Bishop, Paul R. Hutson, Jacquelyn A. Hank, Paul M. Sondel, Wayne L. Furman, Michael M. Meagher, Fariba Navid, Victor M. Santana
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Hu14.18K322A is a humanized anti-GD2 monoclonal antibody with a single point mutation that reduces complement-mediated cytotoxicity, with a maximum tolerated dose (MTD) of 60 mg/m2 daily for 4 days in children with recurrent/refractory neuroblastoma.
Externí odkaz:
https://doaj.org/article/940c5599493e4765891a98b5a77da59b
Autor:
Keng Hee Peh, Daniel J Przybylski, Michael J Fallon, Jason J Bergsbaken, Paul R Hutson, Menggang Yu, Dustin A Deming, Mark E Burkard
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522210912
Purpose Molecular tumor boards provide precision treatment recommendations based on cancer genomic profile. However, practical barriers limit their benefits. We studied the clinical utility of the precision medicine molecular tumor board (PMMTB) and
Publikováno v:
PLoS ONE, Vol 9, Iss 6, p e100770 (2014)
Inflammation of the prostate is strongly correlated with development of lower urinary tract symptoms and several studies have implicated prostatic fibrosis in the pathogenesis of bladder outlet obstruction. It has been postulated that inflammation in
Externí odkaz:
https://doaj.org/article/4574df949489404cbc3889bcf561cf23
Autor:
Paul M. Sondel, Michael W. Bishop, Victor M. Santana, Paul R. Hutson, Jacquelyn A. Hank, Fariba Navid, Michael M Meagher, Wayne L. Furman
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Hu14.18K322A is a humanized anti-GD2 monoclonal antibody with a single point mutation that reduces complement-mediated cytotoxicity, with a maximum tolerated dose (MTD) of 60 mg/m2 daily for 4 days in children with recurrent/refractory neuroblastoma.
Publikováno v:
Clinical pharmacology in drug developmentReferences. 10(1)
Psilocybin is being developed for treating major depressive disorder. Psilocybin is readily dephosphorylated to psilocin upon absorption. The potential for psilocin proarrhythmic effect was assessed using a concentration-QTc interval (C-QTc) analysis
Autor:
Christopher R. Nicholas, Nicholas V. Cozzi, Randall Brown, Michele Gassman, Chantelle Thomas, Paul R. Hutson, Karen M. Cooper, Scott Hetzel, Daniel Muller, Kelsey M. Henriquez
Publikováno v:
J Psychopharmacol
Aim: The aim of the current study was to investigate the relationship between escalating higher doses of psilocybin and the potential psilocybin occasioned positive subjective effects. Methods: Healthy participants ( n=12) were given three escalating
Autor:
Rachel C. Brennan, Barry L. Shulkin, Shenghua Mao, Alberto S. Pappo, Paul M. Sondel, M. Beth McCarville, Wayne L. Furman, Victor M. Santana, Wing Leung, Catherine Y.C. Ng, Paul R. Hutson, William E. Janssen, Aaron Shafer, Sara M. Federico, Michael M Meagher, Jianrong Wu, Jacquelyn A. Hank
Publikováno v:
Clin Cancer Res
Purpose: Anti-GD2 mAbs, acting via antibody-dependent cell-mediated cytotoxicity, may enhance the effects of chemotherapy. This pilot trial investigated a fixed dose of a unique anti-GD2 mAb, hu14.18K322A, combined with chemotherapy, cytokines, and h
Publikováno v:
Drugs in R&D
Introduction Patient adherence to a medication regimen is usually expressed as an adherence rate, defined as the proportion of prescribed doses actually taken. An adherence rate threshold, above which the therapeutic effect is maintained, is typicall